Active Ingredient History
Hyaluronidases are a family of enzymes that catalyse the degradation of hyaluronic acid. Karl Meyer classified these enzymes in 1971, into three distinct groups, a scheme based on the enzyme reaction products. The three main types of hyaluronidases are two classes of eukaryotic endoglycosidase hydrolases and a prokaryotic lyase-type of glycosidase. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia, Hemolytic (Phase 1)
Anesthesia and Analgesia (Early Phase 1)
Arthritis, Rheumatoid (Phase 4)
Breast Neoplasms (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Pancreatic Ductal (Phase 3)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Transitional Cell (Phase 2)
CREST Syndrome (Early Phase 1)
Dehydration (Phase 4)
Dermal Fillers (Phase 1)
Dermatitis, Allergic Contact (Phase 2)
Diabetes Mellitus (Phase 1)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetes Mellitus, Type 2 (Phase 2)
Diagnostic Self Evaluation (Phase 1)
Disaster Medicine (Phase 1)
Edema (Phase 4)
Endometrial Neoplasms (Phase 2/Phase 3)
Esophageal Neoplasms (Phase 1/Phase 2)
Graft Rejection (Phase 2)
Graves Ophthalmopathy (Phase 2)
Healthy Volunteers (Phase 4)
Heart Transplantation (Phase 2)
HIV Antibodies (Phase 1)
HIV Infections (Phase 1)
Hypercholesterolemia (Phase 1)
Immunoglobulin Light-chain Amyloidosis (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 1)
Leukemia, Myeloid (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Lung Neoplasms (Phase 2)
Lymphedema (Phase 1/Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 3)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 3)
Microstomia (Early Phase 1)
Multiple Myeloma (Phase 3)
Multiple Sclerosis (Phase 1)
Muscle Spasticity (Phase 2)
Neoplasms (Phase 2)
Neoplasms by Site (Phase 1/Phase 2)
Nerve Degeneration (Phase 3)
Osteoporosis (Phase 1)
Ovarian Neoplasms (Phase 2)
Pain (Phase 4)
Pain, Postoperative (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 2)
Peripheral Nervous System Diseases (Phase 2)
Polyradiculoneuropathy (Phase 3)
Primary Immunodeficiency Diseases (Phase 3)
Prostatic Neoplasms (Phase 2)
Psoriasis (Phase 2)
Sarcoma (Phase 2)
Scleroderma, Localized (Early Phase 1)
Scleroderma, Systemic (Early Phase 1)
Scleromyxedema (Early Phase 1)
Shoulder Injuries (Phase 3)
Smoldering Multiple Myeloma (Phase 3)
Surgical Wound Infection (Phase 4)
Trismus (Phase 4)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
Uterine Neoplasms (Phase 2/Phase 3)
Venous Cutdown (Phase 1)
Vision, Ocular (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
